Cellectar Biosciences, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Cellectar Biosciences, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Debt Due Cover Ratio: Operating cash was negative last year, while some debt falls due within a year. Lower than 93% of Healthcare companies in United States.
- Shareholder Slice Ratio: Share count rose 1,255% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than 91% of Healthcare companies in United States.
- Cash Cushion Ratio: Cash, after subtracting all debt, is 1.2 times its market value (net cash). Higher than 90% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
-105.8×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 82% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 1/3Sales grew in 0 of the last 3 years; profit grew in 1 of 3.
Less steady than 86% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-230.7×Operating cash was negative last year, while some debt falls due within a year.
Lower than 93% of Healthcare companies in United States.
Cash Cushion Ratio
1.2× cashCash, after subtracting all debt, is 1.2 times its market value (net cash).
Higher than 90% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
Cellectar Biosciences, Inc. made a loss over the last year. Cellectar Biosciences, Inc. owes $0.18 for every $1 it owns. Cellectar Biosciences, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossCellectar Biosciences, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
0.37The share price is 0.37 times Cellectar Biosciences, Inc.'s book value per share, lower than 94% of Healthcare companies in United States.
Market cap
$11 MThe total market value of all of Cellectar Biosciences, Inc.'s shares at today's price (share price × number of shares), smaller than 87% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
$30 MWhat Cellectar Biosciences, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$3.16Net worth divided by the number of shares. The share price of $1.17 is 0.4 times this, which is the P/B above.
Return on equity (ROE)
-119.6%Cellectar Biosciences, Inc. lost 119.6% of its shareholders' money over the last year, lower than 76% of Healthcare companies in United States.
Owes vs Owns
0.18×Cellectar Biosciences, Inc. owes $0.18 for every $1 it owns (low), lower than 75% of Healthcare companies in United States.
Dividend yield
NoneCellectar Biosciences, Inc. does not currently pay a dividend.
Profit growth
LossCellectar Biosciences, Inc. made a loss in each of the last two years.
Cash vs debt
Net cashCellectar Biosciences, Inc. held $13 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Cellectar Biosciences, Inc.: $11 M ÷ $30 M (30 Jun 2026) = 0.4.
What is Cellectar Biosciences, Inc.'s return on equity?
Cellectar Biosciences, Inc. lost 119.6% of its shareholders' money over the last year, lower than 76% of Healthcare companies in United States.
How much does Cellectar Biosciences, Inc. owe compared with what it owns?
Cellectar Biosciences, Inc. owes $0.18 for every $1 it owns (low), lower than 75% of Healthcare companies in United States.
Does Cellectar Biosciences, Inc. pay a dividend?
No. Cellectar Biosciences, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.